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The Journal of Immunology
Candida albicans Primes TLR Cytokine Responses through
a Dectin-1/Raf-1–Mediated Pathway
Daniela C. Ifrim,*,† Leo A. B. Joosten,*,† Bart-Jan Kullberg,*,† Liesbeth Jacobs,*,†
Trees Jansen,*,† David L. Williams,‡ Neil A. R. Gow,x Jos W. M. van der Meer,*,†
Mihai G. Netea,*,† and Jessica Quintin*,†
The immune system is essential to maintain homeostasis with resident microbial populations, ensuring that the symbiotic host–
microbial relationship is maintained. In parallel, commensal microbes significantly shape mammalian immunity at the host
mucosal surface, as well as systemically. Candida albicans is an opportunistic pathogen that lives as a commensal on skin and
mucosa of healthy individuals. Little is known about its capacity to modulate responses toward other microorganisms, such as
colonizing bacteria (e.g., intestinal microorganisms). The aim of this study was to assess the cytokine production of PBMCs
induced by commensal bacteria when these cells were primed by C. albicans. We show that C. albicans and b-1,3-glucan induce
priming of human primary mononuclear cells and this leads to enhanced cytokine production upon in vitro stimulation with TLR
ligands and bacterial commensals. This priming requires the b-1,3-glucan receptor dectin-1 and the noncanonical Raf-1 pathway.
In addition, although purified mannans cannot solely mediate the priming, the presence of mannosyl residues in the cell wall of C.
albicans is nevertheless required. In conclusion, C. albicans is able to modify cytokine responses to TLR ligands and colonizing
bacteria, which is likely to impact the inflammatory reaction during mucosal diseases. The Journal of Immunology, 2013, 190:
4129–4135.
I
mmediately after birth, the gastrointestinal tract is colonized
by a diverse array of microbes, leading to a stable microbiota
that is unique to each individual (1). The human body consists
of trillions of somatic cells and harbors about 10 times more
microorganisms in the intestines (2). The adult microbiota is
composed of permanent members (up to 1000 species), as well as
transient colonizers that are acquired from external sources. It
consists of many prokaryotic and eukaryotic microbes, but bac-
terial species dominate. The most common anaerobic bacteria
within the gastrointestinal tract are Bacteroides, Bifidobacterium,
Eubacterium, Fusobacterium, Clostridium, and Lactobacillus
species (3). These organisms are present in extremely high con-
centrations and have evolved to degrade a variety of dietary
substances, simultaneously enhancing the host digestive efficiency,
as well as their own nutrient supply (4).
In addition to their beneficial effects, gut microorganisms may
be deleterious: when host defense is compromised, theymay invade
host tissues, which leads to mucosal and sometimes subsequent
disseminated infection. A role for the gut flora in the pathogenesis
of autoinflammatory diseases, such as Crohn’s disease and ul-
cerative colitis, has also long been suggested (5). Hence, the im-
mune system controls microbial composition; conversely, the gut
microflora shapes immunity (6). Commensal microbes influence
mucosal and systemic immunity, lymphoid structure development
and epithelial function, T cell subsets, and innate lymph cells (6).
Candida albicans is primarily a human commensal of the skin
and mucous membranes; however, under circumstances of dis-
turbed host defense, it may become a pathogen (7, 8). The dual
consequences of C. albicans colonization and/or infection suggest
that this fungus might modulate the host immune response against
other colonizing microorganisms. It was demonstrated that C.
albicans triggers differential immune signaling upon interaction
with either inflammatory or tolerogenic dendritic cells (9). The
role of C. albicans in experimental colitis is controversial: on one
hand it may activate dendritic cells in Peyer’s patches (9), whereas
on the other hand it may increase the severity of colitis (10, 11).
Nevertheless, all of these studies were performed in mice, and it is
not known whether Candida modulates inflammation in human
primary cells.
In this study, using human primary cells, we investigated whether
C. albicans is able to modulate cytokine responses to secondary
stimuli, such as TLR ligands and colonizing microorganisms, by
inducing either inflammation or tolerance. We established that C.
albicans and, more specifically, b-1,3-glucan (b-glucan) can ef-
ficiently prime human immune cell responses to TLRs and bac-
teria, leading to enhanced cytokine production in vitro. By
deciphering the receptor-signaling pathway involved (dectin-1/
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Raf-1), we also provide a possible novel therapeutic target in
autoinflammatory disorders.
Materials and Methods
Blood samples
Blood was collected from healthy volunteers at Sanquin Bloodbank in
Nijmegen, The Netherlands after obtaining informed consent. Human
PBMCs were isolated from buffy coats.
Reagents
Ficoll-Paque (GE Healthcare) was used to isolate PBMCs by differential
centrifugation. RPMI 1640 Dutch Modification (RPMI) (Sigma-Aldrich),
supplemented with 1% gentamicin, 1% L-glutamine, and 1% pyruvate
(Life Technologies, Nieuwekerk, The Netherlands) was used as culture
medium. Candida b-glucan and mannan were isolated and purified as de-
scribed previously (12, 13). Three sources of C. albicans mannan were
tested: mannan serotype A, mannan isolated fromC. albicans yeast grown in
yeast extract/peptone/dextrose broth at 30˚C (pronase treated), and mannan
isolated from C. albicans hyphae grown in serum at 37˚C (not treated with
pronase). Pam3Cys4 (EMC microcollections) and LPS (Escherichia coli
serotype 055:B5) were purchased from Sigma-Aldrich, with an additional
purification step for LPS (14). Human dectin-1/CLEC7A mAb and isotype
Ab were purchased from R&D Systems (Abingdon, U.K.).
Microorganisms
C. albicans ATCC MYA-3573 (UC 820), och1D, och1D/och1D/OCH1,
pmrD, pmr1D/pmr1D/PMR1, mnn4D, mnn4D/mnn4D/MNN4, and the pa-
rental strain C. albicans NGY152 were grown overnight to yeast cells in
Sabouraud broth at 37˚C. Cells were harvested by centrifugation, washed
twice with PBS, and resuspended in culture medium (RPMI; ICN Bio-
medicals, Aurora, OH). C. albicans yeast was heat-killed for 30 min at
95˚C. To generate hyphae, yeast cells were grown at 37˚C in culture
medium adjusted to pH 6.4 using hydrochloric acid. Hyphae were killed
by exposure to 95˚C for 30 min and resuspended in culture medium to a
hyphal inoculum size that originated from 13 106/ml. The OCH1 gene was
disrupted using the ura-blaster method (15), and the reintegrant strain was
constructed as previously described (16). Creation of the mnn4 null mutant
and of its reintegrant mnn4D/mnn4D/MNN4 control strain was performed as
described (17). The PMR1 gene was disrupted and reintroduced in
pmr1D/pmr1D/PMR1 as described (18). Three common colonizing bac-
teria of the intestines or the skin were chosen: E. coli ATCC 35218 was
grown overnight in culture medium, washed three times with PBS, and
heat-killed for 60 min at 80˚C; Staphylococcus aureus strain Seattle 1945
(ATCC 25923) was grown overnight in culture medium, washed twice with
cold PBS, and heat-killed for 30 min at 100˚C; and Bacteroides fragilis
ATCC 25285 was grown as before but was heat-killed for 30 min at 95˚C.
In vitro cytokine production
The PBMC fraction was obtained by density centrifugation of diluted blood
(1 part blood:1 part pyrogen-free saline) over Ficoll-Paque (GEHealthcare).
PBMCs were washed twice in saline and resuspended in culture medium.
Cells were counted with a Beckman Coulter Z1 Particle Counter and ad-
justed to 5 3 106 cells/ml. PBMCs (5 3 106) were added at a volume of
100 ml/well in round-bottom 96-well plates (Greiner, Nu¨rnberg, Germany).
Cells were incubated with one of the first stimuli for 24 h and reincubated
for another 24 or 48 h with one of the second stimuli. As a priming
stimulus, we used 50 ml either heat-killed C. albicans yeast or hyphae at
two concentrations (1 3 103/ml or 1 3 104/ml), b-glucan (100 mg/ml),
mannan (100 mg/ml), three C. albicans mutants and their corresponding
reintegrants: heat-killed och1D null mutant, pmr1D null mutant, mnn4D
null mutant, och1D/och1D/OCH1, pmr1D/pmr1D/PMR1 and mnn4D/
mnn4D/MNN4 revertant strains (1 3 104/ml), as well as their parental
strain NGY152 (1 3 104/ml). After 24 h, cells were subjected to a second
stimulation with various stimuli, in a volume of 50 ml. The second stimulus
was one of the following: LPS (10 ng/ml), Pam3Cys4 (10 mg/ml), heat-
killed E. coli (1 3 108/ml), heat-killed S. aureus (1 3 107/ml), or heat-
killed B. fragilis (13 107/ml) in a final volume of 200 ml. After 24 or 48 h,
supernatants were collected and stored at 220˚C until assayed. To deter-
mine whether our priming reagents were endotoxin free, we performed
a series of experiments in the presence of polymyxin B. Prior to priming,
the reagents were incubated for 3 h with polymyxin B (2 mg/ml).
To investigate whether priming could be blocked, we preincubated
PBMCs for 1 h with dectin-1/CLEC7A Ab (dectin-1 antagonist; 10 mg/ml)
or with the isotype control (10 mg/ml), Syk inhibitor (50 nM) or Raf-1
inhibitor (1 mM), before priming with b-glucan. After this, cells were
treated with either RPMI or b-glucan (100 mg/ml) and incubated for 24 h,
followed by a second stimulation with LPS (10 ng/ml) for an additional
24 h. Cytokines were measured after the second stimulation.
Cytokine assay
The concentrations of TNF-a and IL-1b (R&D Systems) and IL-6 and IL-
10 (Sanquin, Amsterdam, The Netherlands) were measured in cell culture
supernatants using ELISA, according to the manufacturer’s instructions.
Proinflammatory cytokines TNF-a, IL-1b, and IL-6 were measured at 24 h
after the second stimulation, whereas the anti-inflammatory cytokine IL-10
was measured at 48 h after the second stimulation.
Statistical analysis
Results from at least two sets of experiments with a minimum four vol-
unteers were pooled and analyzed with SPSS. Data are given as mean 6
SEM. The paired Wilcoxon test was used to compare differences between
the effect of a particular stimulus and the RPMI medium control. The level
of significance was set at p , 0.05.
Results
C. albicans primes the cytokine responses of cells restimulated
with TLR ligands and colonizing bacteria
To investigate the effect of C. albicans on the cytokine responses
to colonizing bacteria, PBMCs from healthy donors were first
exposed to low doses of C. albicans. After 24 h, cells were re-
stimulated with common colonizing bacteria of the skin or gut or
with pure components of the bacterial or fungal cell wall (Fig.
1A). Exposure to either C. albicans yeast or hyphae enhanced the
production of TNF-a, IL-6, and IL-1b (Fig. 1B, 1C) of PBMCs
incubated with a second bacterial stimulus, such as E. coli, S.
aureus, or B. fragilis. This priming effect was also observed when
bacterial cell wall components, such as LPS, found in the outer
membrane of Gram-negative bacteria, and the lipopeptide analogs
of the N terminus of bacterial lipoprotein, Pam3Cys4, were used as
a second stimulus. Notably, the increased production of proin-
flammatory cytokines did not correlate with a decrease in the anti-
inflammatory cytokine IL-10 (Fig. 1B, 1C). A 10-fold lower
concentration of C. albicans yeast or hyphae was also able to
prime but to a lesser extent (∼2-fold less).
Mannans do not prime cytokine production by themselves but
are essential for potentiation by C. albicans
The outer layer of the cell wall of C. albicans is enriched with
mannoproteins, whereas the inner layer is composed of chitin and
b-glucan and b-1,6-glucan (19). Mannosylated proteins and
phospholipomannan of C. albicans are known to induce proin-
flammatory cytokines (20, 21). Therefore, we assessed the priming
effect of pure mannans using the in vitro experimental setting
depicted in Fig. 1A. We tested three purified preparations of C.
albicans mannan as priming stimuli; none produced a priming ef-
fect compared with the nonprimed control (Fig. 2).
Because mannans may potentiate priming by other cell wall
components, we used a genetic complementary approach to in-
vestigate the role of specific mannosyl residues. The C. albicans
och1 null mutant has a defect in N-linked mannosylation (Fig.
3A), resulting in a 77% reduction of cytokine production in direct
stimulations (19). In contrast, the C. albicans mnn4 mutant, de-
fective in tertiary branch mannosylphosphorylation (Fig. 3A) (17,
22), has no effect on the direct induction of cytokine production.
C. albicans pmr1 null mutant has a defect in phosphomannosy-
lation, as well as in O- and N-linked glycosylation (18) (Fig. 3A).
In our preincubation model, both C. albicans och1 and pmr1 null
mutants had a partial defect in priming properties and could
not potentiate the production of proinflammatory cytokines to
the same extent as the parental strain (Fig. 3B, 3C). Of note, the
priming effect was restored when cells were exposed to the
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reconstituted strains, och1D/och1D/OCH1 and pmr1D/pmr1D/
PMR1 (Fig. 3B, 3C). The mnn4 null mutant was still able to prime
cytokine production to the same extent as the parental strain C.
albicans NGY152, and the same was true for the reconstituted
strain mnn4D/mnn4D/MNN4 (Fig. 3D). Altogether, these results
show that, although pure mannans do not prime for the production
of proinflammatory cytokines, O- and, especially, N-linked man-
nosyl proteins at the surface of C. albicans are nevertheless re-
quired for the proper priming.
b-glucan primes the response to components of human
microbiota through dectin-1 and Raf-1
Although b-glucan is a component of the inner layer of the
Candida cell wall, it is a potent inducer of cytokines through its
interaction with dectin-1 (23). Therefore, we assessed the effect of
b-glucan in the priming model. Incubation of PBMCs with puri-
fied b-glucan from C. albicans was able to exert a priming effect
similar to that obtained with C. albicans whole organism (Fig.
4A). The effect was most prominent for TNF-a and IL-1b and less
so for IL-6. The b-glucan priming led to a decreased amount of
the anti-inflammatory cytokine IL-10 induced by the secondary
stimuli (Fig. 4A).
When we blocked the dectin-1 receptor with an anti–dectin-1 Ab
before priming with b-glucan, the priming effect was reduced
considerably, whereas the isotype control had no effect (Fig. 4B).
We completed the analysis using PBMCs from two sisters with
congenital dectin-1 deficiency (24). In these experiments b-glucan
priming was completely abolished, highlighting the importance of
the dectin-1 receptor in mediating the b-glucan–dependent prim-
ing of cytokine production upon exposure to TLR ligands and
colonizing bacteria (Fig. 4C). Dectin-1 signaling is primarily
mediated by Syk/CARD9 (25). The inhibition of Syk kinase be-
fore b-glucan stimulation did not affect the priming and subse-
quent enhancement of TNF-a release upon LPS restimulation
(Fig. 4D). However, inhibiting the noncanonical serine-threonine
Raf-1 kinase (26) significantly decreased the priming effect (Fig.
4E). Altogether, these results show that b-glucan, a major compo-
nent of the cell wall of C. albicans, exerts a strong priming effect
toward restimulation with TLR ligands and colonizing bacteria and
that this effect is mediated through the b-glucan receptor dectin-1
and the noncanonical Raf-1 kinase pathway.
Because live C. albicans cell walls consist of b-glucan masked
by a layer of mannosylated proteins, it is possible that the si-
multaneous priming of PBMCs with b-glucan and mannan indu-
ces the production of proinflammatory cytokines to the same
extent as does whole Candida. However, the priming effect of the
two major C. albicans cell wall components, b-glucan and man-
nan, was not different from that of b-glucan alone (Fig. 5). These
results underscore our observation that the priming of C. albicans
is due to b-glucan and not to mannan.
FIGURE 1. C. albicans primes the cytokine respon-
ses of cells restimulated with TLR ligands and colo-
nizing bacteria. (A) In vitro priming scheme. PBMCs
were incubated with C. albicans (priming stimulus) for
24 h at 37˚C. Thereafter, bacteria found in the human
microbiota, as well as their cell wall pure components,
were added (second stimuli) for an additional 24 or
48 h. PBMCs were exposed to RPMI or heat-killed C.
albicans yeast (B) or hyphae (C) (1 3 104 cells/ml).
After 24 h, PBMCs were exposed to several pure
ligands or heat-killed bacteria. Cytokines were mea-
sured in supernatants 24 h (TNF-a, IL-1b, and IL-6)
and 48 h (IL-10) after the second stimulation (n = 6;
three independent experiments). Bars indicate mean +
SEM. *p , 0.05 versus RPMI–primed cells, Wilcoxon
nonparametric test for two related samples. Bf, B.
fragilis; Ec, E. coli; P3C, Pam3Cys4; Sa, S. aureus.
The Journal of Immunology 4131
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Priming is not due to endotoxin contamination
Prior to priming, all stimuli (RPMI, b-glucan, and mannan) were
incubated with cell culture medium (control) or with polymyxin B
for 3 h at 37˚C. Thereafter, PBMCs were primed for 24 h and then
restimulated with LPS, Pam3Cys4 or cell culture medium only
(RPMI) for an additional 24 h (Supplemental Fig. 1). Polymyxin B
treatment of b-glucan did not affect its ability to prime PBMCs,
excluding the effect of endotoxin contamination in the described
effect. Mannan was still not able to prime, either with or without
polymyxin B. In addition, b-glucan and polymyxin B priming was
FIGURE 2. By themselves, mannans do not prime cytokine production, but they are essential for potentiation by C. albicans. PBMCs were exposed to
either RPMI or C. albicans mannan isolated from C albicans hyphae grown in serum at 37˚C at a concentration of 100 mg/ml. After 24 h, PBMCs were
restimulated with several pure ligands or heat-killed bacteria. Cytokines were measured in supernatants 24 h (TNF-a, IL-1b, and IL-6) and 48 h (IL-10)
after the second incubation. Three types of C. albicans mannan were tested, but none of them induced priming compared with the nonprimed control (n $
5; two independent experiments). No statistical differences were detected using the Wilcoxon nonparametric test for two related samples. Ec, E. coli; P3C,
Pam3Cys4; Sa, S. aureus.
FIGURE 3. Mannosylation of fungal cell wall proteins is involved in the potentiation of cytokine production. (A) Schematic diagram representing the
activity of Och1, Pmr1, and Mnn4 enzymes on C. albicans cell wall glycosylation. For N-mannosylation, the Och1 mannosyltransferase mediates the
addition of the first a-1,6-mannose to the core N-mannan structure. Two a-1,6-mannose residues form the backbone onto which a-1,2-mannose– and a-1,3-
mannose–linked mannose residues are subsequently attached by different enzymes to form the N-linked outer chain. Phosphomannan is attached to this
outer chain via a phosphodiester bond, which requires Mnn4. Pmr1 is not a glycosyltransferase and does not add any mannans directly but exerts its effects
on both N-mannosylation and O-mannosylation. The arrows represent where truncations in N-mannosylation and O-mannosylation occur. (B–D) PBMCs
were exposed to NGY152, och1D, pmr1D, mnn4D, och1D/och1D/OCH1, pmr1D/pmr1D/PMR1, or mnn4D/mnn4D/MNN4 (104 cells/ml). After 24 h,
PBMCs were restimulated with heat-killed bacteria. Cytokines (IL-1b and IL-6) were measured in supernatants 24 h after the second incubation (n = 10;
four independent experiments). Bars indicate mean 6 SEM. All C. albicans strains induced a significant increase in proinflammatory cytokine production
compared with nonprimed (RPMI) cells, whereas och1D and pmr1D null mutants resulted in significantly less priming of cytokine production compared
with the parental strain or their corresponding reconstituted strains. *p , 0.05, **p , 0.01, ***p , 0.001, Wilcoxon nonparametric test for two related
samples. Ec, Escherichia coli; Sa, S. aureus.
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completely abrogated when PBMCs were restimulated with LPS;
this was not the case for the same mix and restimulation with
Pam3Cys4.
Discussion
In the current study, we analyzed the capacity of the human
commensal yeast C. albicans to modulate the cytokine response of
human primary cells to bacteria that usually colonize the skin and
mucosal surfaces. C. albicans, either yeast or hyphae, primes the
cells for enhanced proinflammatory cytokine production when
they are exposed to a secondary bacterial stimulus. This priming
activity is dependent on carbohydrate components of the cell wall
of Candida, with an important role for the recognition of b-glucan
by the dectin-1/Raf-1 pathway.
An important aspect is which molecular pattern of C. albicans
is responsible for this increased immune activity. Combining pu-
FIGURE 4. b-glucan primes the re-
sponse to components of human micro-
biota. (A) PBMCs were incubated with
RPMI or b-glucan (100 mg/ml). After
24 h, PBMCs were reincubated with pure
ligands or heat-killed bacteria. Cytokines
were measured in supernatants 24 h
(TNF-a, IL-1b, and IL-6) and 48 h (IL-
10) after the second stimulation (n = 11;
five independent experiments). (C)
PBMCs from 16 healthy volunteers and
2 dectin-1–deficient sisters (24) were
incubated with RPMI and b-glucan (100
mg/ml) for 24 h, followed by a second
stimulation with either TLR ligands or
whole bacteria for an additional 24 h.
PBMCs were incubated with RPMI,
CLEC7A Ab, and the isotype control (10
mg/ml) (B), Syk inhibitor (1 mM) (D), or
Raf-1 inhibitor (50 nM) (E). After 1 h of
incubation, cells were treated either with
RPMI or b-glucan (100 mg/ml) and, after
an additional 24 h, restimulated with
LPS. For (B), n = 7; three independent
experiments; for (D) and (E), n = 10; five
independent experiments. Bars indicate
mean 6 SEM. *p , 0.05, **p , 0.01
versus RPMI–stimulated cells, Wilcoxon
nonparametric test for two related sam-
ples. Bf, B. fragilis; Ec, E. coli; P3C,
Pam3Cys4; Sa, S. aureus.
FIGURE 5. Priming with a combination of b-glucans and mannans. PBMCs were incubated simultaneously with b-glucan and mannan (100 mg/ml);
after 24 h, cells were stimulated either with TLR ligands or with whole bacteria for an additional 24 h (n = 7; three independent experiments). Bars indicate
mean6 SEM. *p, 0.05, **p, 0.01 versus RPMI–stimulated cells, Wilcoxon nonparametric test for two related samples. Ec, E. coli; P3C, Pam3Cys4; Sa,
S. aureus.
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rified cell wall components and genetic approaches, we established
that fungal mannan itself does not prime PBMCs for the pro-
duction of cytokines. Surprisingly, however, neither the och1 nor
the pmr1 null C. albicans mutant was able to prime the production
of proinflammatory cytokines at the same extent as was wild-type
C. albicans or parental strain NGY152, whereas the use of
a reconstituted strain entirely restored the priming effect. Thus,
the presence of the O- and N-linked mannosyl proteins at the
Candida cell surface is required for proper priming, supposedly by
aiding cell priming by an additional cell wall component. Of note,
although, under aqueous conditions, long chains of purified
b-glucan form a right-handed triple helical complex that is re-
quired for the proper binding to pattern recognition receptors (27–
29), purified mannan might not have the required structure to be
recognized by its receptor, offering an alternative explanation for
the lack of priming induced by pure mannans. Different biological
effects of mannans were reported, including induction of proin-
flammatory cytokines (19, 30) and of IL-10 (31). It was shown
that when C. albicans mannoprotein was administered to mice
before or during immunization with viable C. albicans, it down-
regulated mannan-specific delayed hypersensitivity (32), whereas
mannoproteins confer protection to candidiasis and might contain
epitopes involved in this protective response (32). In this study, we
show that mannans incorporated in Candida cell wall have adju-
vant activity for the priming effect exerted by this yeast.
In search of the main component of the Candida cell wall that
induces priming, we demonstrate that b-glucan can mimic the
priming effect obtained upon C. albicans preincubation. This ef-
fect of b-glucan is in line with previous studies showing that
b-glucan is an immunostimulant and, moreover, displays antitu-
mor activity (33, 34). The receptor mediating the priming effects
of b-glucans is dectin-1, as shown by experiments with cells ge-
netically deficient for this receptor. Downstream signaling occurs
via two pathways: the canonical Syk/CARD9 and the non-
canonical serine-threonine kinase Raf-1 (25, 26, 35). We found
that inhibition of Syk kinase, prior to exposure to b-glucan, did
not influence the priming activity of b-glucan. In contrast, the
incubation of PBMCs with a Raf-1 inhibitor prior to first stimu-
lation significantly reduced the effect. This observation distin-
guishes the direct effect of dectin-1 stimulation (Syk dependent)
from the priming effect mediated by dectin-1 (Raf-1 dependent).
Indeed, a previous study showed a dual intracellular signaling
upon dectin-1 activation, in which the Raf-1 pathway integrates
with the Syk pathway at the level of NF-kB (35). Because priming
is induced by purified TLR ligands, which are important compo-
nents of bacteria, we tend to conclude that the priming induced
by Candida and b-glucans acts on TLR-dependent–signaling
pathways.
C. albicans is a common commensal of the intestinal tract, and
it was reported to increase the severity of intestinal inflammation
in murine models of colitis (10, 11). The b-glucan receptor dectin-
1 is involved in this effect, and polymorphisms in this receptor
have been associated with the severity of ulcerative colitis (11) but
not with the susceptibility to ulcerative colitis or Crohn’s disease
(36). Little is known about the mechanisms through which C.
albicansmay influence autoinflammatory diseases, such as Crohn’s
disease. Although simultaneous stimulation of cells with Candida-
derived polysaccharides and TLR ligands is known to be syner-
gistic for cytokine induction, it is not known whether prestimu-
lation of immune cells with Candida can prime or tolerize (as in
the case of TLR stimulation with LPS or Pam3Cys4) the cells for
subsequent stimulation with colonizing bacteria. In the current
study, we demonstrate that preincubation of human primary cells
with C. albicans primes them for the production of cytokines, and
this amplification of inflammation may represent one mechanism
for the increased severity of colitis induced by Candida. The
priming effect found in this study may be relevant for these
observations. Whether this effect of Candida is also relevant for
inflammatory bowel disease in humans is not clear. However,
because Abs toward C. albicans were shown to be associated
specifically with Crohn’s disease, one may speculate that Candida
plays a role in this disease (37). It is attractive to hypothesize that
this has to do with the priming effect described in this article.
Chronic stimulation of host immune cells by microorganisms
may result in an enhanced functional state and, hence, increased
resistance to infection or in immunosuppression (or tolerance). The
latter may imply protection against tissue damage. Understanding
the interplay between these two strategies may allow us to define
how fungi adapt to the human immune system. It was proposed that
C. albicans may either promote tolerance (9) or amplify inflam-
mation and contribute to disease activity in Crohn’s disease (11).
In the current study, C. albicans did not induce tolerance, but it
promoted the proinflammatory response of human primary cells to
colonizing bacteria. Such priming may be related to the epigenetic
reprogramming of C. albicans described in monocytes (38). Thus,
the fungal microbiota may actively contribute to the state of host
defense at mucosal sites. When leukocytes at the mucosal sites
previously primed by C. albicans encounter potentially pathogenic
colonizing bacteria, the enhanced state of the host response may
potentiate the defense (e.g., by recruitment and activation of ef-
fective immune cells and by induction of diffusion in mucosal
sites).
In conclusion, we demonstrate that chronic exposure of primary
human immune cells to C. albicans primes them for subsequent
stimulation with TLR ligands and colonizing microorganisms,
a mechanism that could explain the effects of this fungus on in-
flammatory bowel diseases. By identifying dectin-1/Raf-1 as one
of the pathways responsible for these effects, we provide a po-
tential therapeutic target in autoinflammatory diseases, such as
Crohn’s disease. Further studies are warranted to assess this hy-
pothesis.
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